It acts as the core quinoxaline structure that is brominated and coupled with an imidazoline moiety (such as N-acetyl ethylene urea or imidazoline sulfonic acid) to form the final compound, with high-yield, safe, and efficient processes often involving bromination using dibromohydantoin. 6-Quinoxalinamine (specifically 5-bromo-6-quinoxalinamine) is a key intermediate in the synthesis of Brimonidine tartrate, a glaucoma medication.
6-Quinoxalinamine
| API Name | Brimonidine tartrate |
|---|---|
| CAS No | 6298-37-9 |
| Molecular Formula | C8H7N3 |
| Molecular Weight | 145.16 g/mol |
| Synonyms | quinoxalin-6-amine |
Zoho Contact Form - Pharma Intermediates
"*" indicates required fields
Frequently Asked Questions
It acts as the core quinoxaline structure that is brominated and coupled with an imidazoline moiety (such as N-acetyl ethylene urea or imidazoline sulfonic acid) to form the final compound, with high-yield, safe, and efficient processes often involving bromination using dibromohydantoin. 6-Quinoxalinamine (specifically 5-bromo-6-quinoxalinamine) is a key intermediate in the synthesis of Brimonidine tartrate, a glaucoma medication.
The CAS number of 6-Quinoxalinamine is 6298-37-9.
The molecular formula of 6-Quinoxalinamine is C8H7N3.
The listed molecular weight of 6-Quinoxalinamine is 145.16 g/mol.
6-Quinoxalinamine is listed as being used in connection with the following API: Brimonidine tartrate.
The listed synonym or IUPAC name for 6-Quinoxalinamine is quinoxalin-6-amine.